---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-084206"
form_type: "8-K"
ticker: "GRDX"
cik: "0001604191"
company_name: "GridAI Technologies Corp."
filed_at: "2024-07-31T23:59:59+00:00"
generated_at: "2026-05-31T14:23:22.793215+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Entero Therapeutics provides latiglutenase Phase 3 plan, FDA meetings, $1.9M raise

## Summary
- Submits Type D requests to FDA to streamline Phase 3 trial cohorts from three to two (1200 mg and placebo).
- Second Type D request seeks FDA agreement on histology secondary endpoints based on Phase 2 results.
- Raised $1.9 million in gross proceeds from a small financing to support Phase 3 trial initiation.
- Consolidated bi-coastal operations into Boca Raton HQ to reduce overhead costs.
- CEO James Sapirstein reaffirms goal to start pivotal Phase 3 trial for latiglutenase in 2025.

## SEC filing metadata
- accession: 0001104659-24-084206
- form_type: 8-K
- ticker: GRDX
- cik: 0001604191
- company_name: GridAI Technologies Corp.
- filed_at: 2024-07-31T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1604191/000110465924084206/0001104659-24-084206-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1604191/000110465924084206/tm2420546d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-084206
- JSON: https://secwatch.observer/filing/0001104659-24-084206.json
- Plain text: https://secwatch.observer/filing/0001104659-24-084206.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.